B. Conrad

TL;DR: The GeparSepto (GBG 69) trial assessed whether weekly nab-paclitaxel could increase the proportion of patients achieving pathological complete response compared with weekly solvent-based pac Litaxel, both followed by epirubicin plus cyclophosphamide as neoadjuvant treatment.

TL;DR: Premenopausal patients with breast cancer receiving goserelin simultaneously with modern neoadjuvant chemotherapy did not experience statistically significantly less amenorrhea 6 months after end of chemotherapy compared with those receiving chemotherapy alone.

TL;DR: A novel model of SFTS in hamsters genetically engineered to be deficient in a protein that helps protect humans and animals against viral infections is described, which suggests that the new SFTS model will be an excellent resource to better understand SFTSV infection and disease as well as a valuable tool for evaluating promising antiviral therapies.

TL;DR: Adjuvant treatment with oral ibandronate did not improve outcome of patients with high-risk early breast cancer who received dose-dense chemotherapy and was not enough to demonstrate an increase in disease-free survival.

TL;DR: Although greater than 40% of breast cancers occur in patients aged ≥65 years, these individuals are frequently undertreated and taxane‐based adjuvant chemotherapy is considered the treatment of choice but to the authors' knowledge has only limited evidence in elderly patients.